Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety
and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the
treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell
lymphoma.